ACE-031 vs CJC-1295 + GHRP-6 Stack
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
ACE-031
Soluble form of activin type IIB receptor (ActRIIB-Fc fusion protein) that acts as a myostatin and activin trap. Blocks the primary signals that limit muscle growth by sequestering myostatin, activin, and related ligands before they reach cell surface receptors. Phase 2 trials in Duchenne muscular dystrophy demonstrated significant lean mass increases.
Full profileCJC-1295 + GHRP-6 Stack
CJC-1295 (GHRH analog) combined with GHRP-6 (potent ghrelin receptor agonist) to produce synergistic GH release via complementary mechanisms. GHRP-6's strong appetite stimulation distinguishes this from the CJC-1295 + Ipamorelin stack, making it preferred for bulking and mass-gaining protocols where caloric surplus is the goal. Produces larger GH pulses than CJC + Ipamorelin but with more pronounced appetite effects.
Full profile| ACE-031 | CJC-1295 + GHRP-6 Stack | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | ACVR2B-Fc, ActRIIB-Fc fusion protein | CJC GHRP-6 combination, GH releasing stack, GHRH GHRP combination, CJC-1295 GHRP-6 |
| Evidence | Investigational (in trials) | Research-stage |
| Dosing range | 0.3mg/kg–3mg/kg mg/kg, every 2–4 weeks (subcutaneous injection) | CJC-1295 100mcg + GHRP-6 100mcg–CJC-1295 200mcg + GHRP-6 300mcg mcg, 1–3x daily (pre-sleep, pre-workout, morning) |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Key side effects | Nosebleeds (epistaxis — most common reported AE), Telangiectasia (visible small blood vessel dilation), Gum bleeding, Elevated hemoglobin | Strong appetite stimulation (GHRP-6 dominant effect), Water retention, Tingling / numbness in extremities, Mild cortisol elevation (GHRP-6 is less selective than ipamorelin) |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: ACE-031 is investigational (in trials), while CJC-1295 + GHRP-6 Stack is research-stage.
- Dosing units differ: ACE-031 is dosed in mg/kg, CJC-1295 + GHRP-6 Stack in mcg — they operate at different scales.
- Frequency: ACE-031 is typically every 2–4 weeks (subcutaneous injection); CJC-1295 + GHRP-6 Stack is 1–3x daily (pre-sleep, pre-workout, morning).
How each works
ACE-031
ACE-031 functions as a decoy receptor, binding myostatin, activin A/B, GDF-11, and BMP-9 in circulation before they can activate cellular ActRIIB receptors. In the Duchenne muscular dystrophy Phase 2 trial, ACE-031 produced meaningful lean body mass increases but was halted due to vascular side effects (epistaxis, telangiectasia) requiring dose and safety optimization.
CJC-1295 + GHRP-6 Stack
The GHRH + GHRP combination synergistically amplifies GH pulse amplitude compared to either agent alone. CJC-1295 elevates baseline GH via GHRH receptor signaling at the pituitary; GHRP-6 triggers pulse timing via GHS-R1a. GHRP-6's potent appetite stimulation (significantly stronger than ipamorelin) makes this combination preferred in protocols targeting caloric surplus and mass accumulation.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.